Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018 2019

Details for Mechanism ID: 16787
Country/Region: Tanzania
Year: 2018
Main Partner: John Snow, Inc
Main Partner Program: NA
Organizational Type: Implementing Agency
Funding Agency: USAID
Total Funding: $9,685,919 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $114,609
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $183,375
Care: Pediatric Care and Support (PDCS) $114,609
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $7,393,744
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $527,200
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $1,237,773
Treatment: Pediatric Treatment (PDTX) $114,609
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST <5, Unknown Sex, Negative 2019 56
HTS_TST 15-19, Female, Negative 2019 24
HTS_TST 15-19, Male, Negative 2019 18
HTS_TST 20-24, Female, Negative 2019 57
HTS_TST 20-24, Male, Negative 2019 63
HTS_TST 25-29, Female, Negative 2019 239
HTS_TST 25-29, Female, Negative 2019 239
HTS_TST 25-29, Female, Negative 2019 2,220
HTS_TST 25-29, Female, Negative 2019 1,992
HTS_TST 25-29, Female, Negative 2019 88
HTS_TST 25-29, Female, Negative 2019 372
HTS_TST 25-29, Male, Negative 2019 227
HTS_TST 25-29, Male, Negative 2019 270
HTS_TST 25-29, Male, Negative 2019 2,304
HTS_TST 25-29, Male, Negative 2019 93
HTS_TST 25-29, Male, Negative 2019 386
HTS_TST 25-29, Male, Negative 2019 4,353
HTS_TST 30-34, Female, Negative 2019 301
HTS_TST 30-34, Female, Negative 2019 292
HTS_TST 30-34, Female, Negative 2019 2,630
HTS_TST 30-34, Female, Negative 2019 1,992
HTS_TST 30-34, Female, Negative 2019 116
HTS_TST 30-34, Female, Negative 2019 474
HTS_TST 30-34, Male, Negative 2019 162
HTS_TST 30-34, Male, Negative 2019 190
HTS_TST 30-34, Male, Negative 2019 1,747
HTS_TST 30-34, Male, Negative 2019 66
HTS_TST 30-34, Male, Negative 2019 278
HTS_TST 35-39, Female, Negative 2019 312
HTS_TST 35-39, Female, Negative 2019 318
HTS_TST 35-39, Female, Negative 2019 3,132
HTS_TST 35-39, Female, Negative 2019 1,992
HTS_TST 35-39, Female, Negative 2019 119
HTS_TST 35-39, Female, Negative 2019 511
HTS_TST 35-39, Male, Negative 2019 159
HTS_TST 35-39, Male, Negative 2019 190
HTS_TST 35-39, Male, Negative 2019 1,623
HTS_TST 35-39, Male, Negative 2019 67
HTS_TST 35-39, Male, Negative 2019 272
HTS_TST 40-49, Female, Negative 2019 449
HTS_TST 40-49, Female, Negative 2019 556
HTS_TST 40-49, Female, Negative 2019 4,314
HTS_TST 40-49, Female, Negative 2019 2,998
HTS_TST 40-49, Female, Negative 2019 202
HTS_TST 40-49, Female, Negative 2019 807
HTS_TST 40-49, Male, Negative 2019 377
HTS_TST 40-49, Male, Negative 2019 417
HTS_TST 40-49, Male, Negative 2019 2,859
HTS_TST 40-49, Male, Negative 2019 164
HTS_TST 40-49, Male, Negative 2019 636
HTS_TST 50+, Female, Negative 2019 112
HTS_TST 50+, Male, Negative 2019 67
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 151,702
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 9
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 1,565
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 5,885
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 7
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 49
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 283
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 70
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 115
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 57
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 41
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 139
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 145
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 281
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 176
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 52
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 253
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 59
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 136
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 85
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 56
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 170
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 243
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 323
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 191
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 1,704
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 410
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 753
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 462
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 390
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 1,031
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 2,121
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 3,551
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 1,975
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 944
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 25
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 147
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 30
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 59
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 105
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 78
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 231
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 309
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 506
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 297
HTS_TST Service Delivery Point (Facility) VMMC: 10-14, Negative 2019 46,022
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2019 21,501
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2019 12,336
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 326
HTS_TST_POS 15-19, Female, Positive 2019 1
HTS_TST_POS 15-19, Male, Positive 2019 2
HTS_TST_POS 20-24, Male, Positive 2019 2
HTS_TST_POS 25-29, Female, Positive 2019 24
HTS_TST_POS 25-29, Female, Positive 2019 6
HTS_TST_POS 25-29, Female, Positive 2019 59
HTS_TST_POS 25-29, Female, Positive 2019 55
HTS_TST_POS 25-29, Female, Positive 2019 14
HTS_TST_POS 25-29, Male, Positive 2019 27
HTS_TST_POS 25-29, Male, Positive 2019 13
HTS_TST_POS 25-29, Male, Positive 2019 64
HTS_TST_POS 25-29, Male, Positive 2019 5
HTS_TST_POS 25-29, Male, Positive 2019 13
HTS_TST_POS 30-34, Female, Positive 2019 32
HTS_TST_POS 30-34, Female, Positive 2019 10
HTS_TST_POS 30-34, Female, Positive 2019 76
HTS_TST_POS 30-34, Female, Positive 2019 55
HTS_TST_POS 30-34, Female, Positive 2019 4
HTS_TST_POS 30-34, Female, Positive 2019 18
HTS_TST_POS 30-34, Male, Positive 2019 15
HTS_TST_POS 30-34, Male, Positive 2019 5
HTS_TST_POS 30-34, Male, Positive 2019 42
HTS_TST_POS 30-34, Male, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 10
HTS_TST_POS 35-39, Female, Positive 2019 35
HTS_TST_POS 35-39, Female, Positive 2019 11
HTS_TST_POS 35-39, Female, Positive 2019 85
HTS_TST_POS 35-39, Female, Positive 2019 55
HTS_TST_POS 35-39, Female, Positive 2019 19
HTS_TST_POS 35-39, Male, Positive 2019 14
HTS_TST_POS 35-39, Male, Positive 2019 6
HTS_TST_POS 35-39, Male, Positive 2019 41
HTS_TST_POS 35-39, Male, Positive 2019 9
HTS_TST_POS 40-49, Female, Positive 2019 51
HTS_TST_POS 40-49, Female, Positive 2019 18
HTS_TST_POS 40-49, Female, Positive 2019 132
HTS_TST_POS 40-49, Female, Positive 2019 90
HTS_TST_POS 40-49, Female, Positive 2019 29
HTS_TST_POS 40-49, Male, Positive 2019 49
HTS_TST_POS 40-49, Male, Positive 2019 23
HTS_TST_POS 40-49, Male, Positive 2019 106
HTS_TST_POS 40-49, Male, Positive 2019 28
HTS_TST_POS 50+, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 24
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 187
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 34
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 53
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 86
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 52
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) VMMC: 10-14, Positive 2019 62
HTS_TST_POS Service Delivery Point (Facility) VMMC: 15-19, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) VMMC: 20-24, Positive 2019 3
PMTCT_ART Already on ART at beginning of current pregnancy 2019 420
PMTCT_ART New on ART 2019 460
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 880
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 17,411
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 637
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 229
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 866
PMTCT_EID Sum of Infant Age disaggregates 2019 866
PMTCT_STAT 25-29, Female 2019 4,350
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 117
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 4,117
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 119
PMTCT_STAT 30-34, Female 2019 3,482
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 95
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 3,293
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 94
PMTCT_STAT 35-39, Female 2019 2,612
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 69
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 2,467
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 73
PMTCT_STAT 40-49, Female 2019 521
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 10
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 494
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 11
PMTCT_STAT By Age (Numerator): 10-14 2019 173
PMTCT_STAT By Age (Numerator): 15-19 2019 870
PMTCT_STAT By Age (Numerator): 20-24 2019 5,222
PMTCT_STAT By Age (Numerator): 50+ 2019 173
PMTCT_STAT By Number of known positives: 15-19 2019 18
PMTCT_STAT By Number of known positives: 20-24 2019 141
PMTCT_STAT By Number of new negative: 10-14 2019 166
PMTCT_STAT By Number of new negative: 15-19 2019 821
PMTCT_STAT By Number of new negative: 20-24 2019 4,943
PMTCT_STAT By Number of new negative: 50+ 2019 166
PMTCT_STAT By Number of new positives: 10-14 2019 1
PMTCT_STAT By Number of new positives: 15-19 2019 19
PMTCT_STAT By Number of new positives: 20-24 2019 143
PMTCT_STAT By Number of new positives: 50+ 2019 1
PMTCT_STAT Number of new ANC and L&D clients 2019 18,321
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 17,411
PMTCT_STAT_den 25-29, Female 2019 4,580
PMTCT_STAT_den 30-34, Female 2019 3,664
PMTCT_STAT_den 35-39, Female 2019 2,748
PMTCT_STAT_den 40-49, Female 2019 551
PMTCT_STAT_den By Age (Denominator): <15-19 2019 915
PMTCT_STAT_den By Age (Denominator): 10-14 2019 182
PMTCT_STAT_den By Age (Denominator): 20-24 2019 5,499
PMTCT_STAT_den By Age (Denominator): 50+ 2019 182
TB_PREV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 134
TB_PREV Alternative TPT Regimen, Life-long ART, New, Positive 2019 1,917
TB_PREV By Age/Sex (Numerator): <15, Female 2019 134
TB_PREV By Age/Sex (Numerator): <15, Male 2019 125
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 1,917
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 762
TB_PREV IPT, Life-long ART, Already, Positive 2019 125
TB_PREV IPT, Life-long ART, New, Positive 2019 762
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 2,941
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 3,460
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 154
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 161
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 2,182
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 961
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 84
TB_PREV_den IPT, Life-long ART, New, Positive 2019 3,376
TX_CURR 25-29, Female, Positive 2019 1,475
TX_CURR 25-29, Male, Positive 2019 437
TX_CURR 30-34, Female, Positive 2019 1,871
TX_CURR 30-34, Male, Positive 2019 584
TX_CURR 35-39, Female, Positive 2019 1,714
TX_CURR 35-39, Male, Positive 2019 717
TX_CURR 40-49, Female, Positive 2019 2,223
TX_CURR 40-49, Male, Positive 2019 1,311
TX_CURR Age/Sex: <1 2019 25
TX_CURR Age/Sex: <1-9 2019 314
TX_CURR Age/Sex: 10-14 Female 2019 134
TX_CURR Age/Sex: 10-14 Male 2019 129
TX_CURR Age/Sex: 15-19 Female 2019 267
TX_CURR Age/Sex: 15-19 Male 2019 186
TX_CURR Age/Sex: 20-24 Female 2019 562
TX_CURR Age/Sex: 20-24 Male 2019 294
TX_CURR Age/Sex: 50+ Female 2019 1,698
TX_CURR Age/Sex: 50+ Male 2019 1,158
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 15,105
TX_CURR Sum of age/sex disaggregates 2019 453
TX_NEW 25-29, Female, Positive 2019 176
TX_NEW 25-29, Male, Positive 2019 204
TX_NEW 30-34, Female, Positive 2019 240
TX_NEW 30-34, Male, Positive 2019 124
TX_NEW 35-39, Female, Positive 2019 245
TX_NEW 35-39, Male, Positive 2019 129
TX_NEW 40-49, Female, Positive 2019 449
TX_NEW 40-49, Male, Positive 2019 363
TX_NEW Breastfeeding status 2019 100
TX_NEW By Age/Sex: <1 2019 8
TX_NEW By Age/Sex: 1-9 2019 44
TX_NEW By Age/Sex: 10-14 Female 2019 6
TX_NEW By Age/Sex: 10-14 Male 2019 14
TX_NEW By Age/Sex: 15-19 Female 2019 52
TX_NEW By Age/Sex: 15-19 Male 2019 37
TX_NEW By Age/Sex: 20-24 Female 2019 107
TX_NEW By Age/Sex: 20-24 Male 2019 132
TX_NEW By Age/Sex: 50+ Female 2019 234
TX_NEW By Age/Sex: 50+ Male 2019 150
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 2,737
TX_NEW Pregnancy status 2019 381
TX_NEW Sum of Age/Sex disaggregates 2019 732
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 11,794
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 137
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 40
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 309
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 79
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 7,883
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 44
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 3,273
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 26
TX_PVLS_den Denominator: Indication: Routine 2019 11,659
TX_PVLS_den Denominator: Indication: Targeted 2019 136
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 100
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 44
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 3,179
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,401
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 4,725
TX_RET Numerator by Status: Breastfeeding 2019 104
TX_RET Numerator by Status: Pregnant 2019 625
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 5,254
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 114
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 50
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 3,531
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,553
TX_RET_den Denominator by Status: Breastfeeding 2019 118
TX_RET_den Denominator by Status: Pregnant 2019 695
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 9,227
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 291
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 273
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 5,963
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 2,698
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 197
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 197
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 7,353
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 100
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 1,747
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 20
VMMC_CIRC By Age: 0-60 days 2019 4,084
VMMC_CIRC By Age: 10-14 2019 59,161
VMMC_CIRC By Age: 15-19 2019 28,264
VMMC_CIRC By Age: 20-24 2019 16,212
VMMC_CIRC By Age: 25-29 2019 12,776
VMMC_CIRC By circumcision technique: Device-based VMMC 2019 4,084
VMMC_CIRC By circumcision technique: Surgical VMMC 2019 116,398
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2019 120,481
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2019 116,413
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2019 103,637
Cross Cutting Budget Categories and Known Amounts Total: $4,450,000
Gender: Gender Based Violence (GBV) $50,000
GBV Prevention
Human Resources for Health $4,400,000